SAN DIEGO, April 03, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or the “Company”) today announced that Gregg Lapointe has joined the Company’s Board of Directors to serve as an independent director, effective March 31, 2017.
Mr. Lapointe has over 20 years of experience in the pharmaceutical and medical device industries. He is a Co-Founder and currently serves as the CEO of Cerium Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. Previously, he held several managerial and executive roles at Sigma-Tau Pharmaceuticals including serving as CEO from 2008 to 2012. Prior to that, Mr. Lapointe held various financial and operations roles at AstenJohnson, Medical Plastic Devices, Inc. and Ingram & Bell Meditron. Prior to joining Ingram & Bell Meditron, he served as a Senior Manager at Zittrer Siblin Stein Levine, a management consultant mergers and acquisitions firm based in Montreal, Canada. Mr. Lapointe began his career at Price Waterhouse in 1982 as a Chartered Accountant with progressive advancement from staff accountant to Audit Manager. Mr. Lapointe received a Bachelor of Commerce degree from Concordia University, a Graduate Diploma in Public Accountancy from McGill University and an MBA from Duke University. He is a Certified Public Accountant in Illinois. Mr. Lapointe currently serves as a member of the Board of Directors of SciClone Pharmaceuticals, Soligenix and Immunocellular Therapeutics and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board and as Chair of the Rare Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Board of Directors of Questcor Pharmaceuticals and Raptor Pharmaceutical Corp.
"We are delighted to welcome Gregg to our Board. He is an accomplished executive with highly relevant experiences and competencies leading biopharmaceutical companies through periods of high intensity growth. His business acumen and leadership abilities are important additions at this exciting time of growth and transformation for Cytori," said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics.
"Cytori’s platform technology and late stage HABEO cellular therapeutic have the potential to substantially improve the lives of patients with scleroderma as well as a number of other rare diseases,” commented Mr. Lapointe. "I have been a part of numerous companies at this exciting stage of the corporate lifecycle and feel this technology could be transformative. I believe I can bring the benefit of my experience and orphan commercialization perspective to an already experienced life sciences management team and board of directors."
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 email@example.com